| abstract |
The present invention provides antisense nucleic acid molecules of VEGF 165, antisense nucleic acid molecules of alpha-9 domains that form integrin alpha-9 / beta-1, and antisense nucleic acid molecules of VAP-1, The specific antibody molecule of VEGF 165, the antibody molecule specific for the alpha-9 domain forming integrin alpha-9 / beta-1, and the specific antibody molecule of VAP-1, and An anti-angiogenic pharmaceutical composition comprising at least one molecule selected from the group consisting of / or combinations thereof and a pharmaceutically acceptable carrier. The present invention also protects the use of such molecules for the production of medicaments. |